APA (7th ed.) Citation

LE, B., H, Z., WS, K., D, M., EM, R., L, N., . . . J, W. (2025). Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 43(36), 3799. https://doi.org/10.1200/JCO-25-01957

Chicago Style (17th ed.) Citation

LE, Budde, et al. "Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 43, no. 36 (2025): 3799. https://doi.org/10.1200/JCO-25-01957.

MLA (9th ed.) Citation

LE, Budde, et al. "Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 43, no. 36, 2025, p. 3799, https://doi.org/10.1200/JCO-25-01957.